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OBJECTIVES: To estimate the budget impact of saxagliptin/metformin XR fixed-
dose combination introduction as a treatment option for patients with type 2 
diabetes mellitus (T2DM), compared to the present situation, in Chile. METHODS: 
An MS Excel-based budget impact model assuming coverage for one million 
people. The time horizon was three years and the analysis perspective was the 
National health Insurance system in Chile (FONASA). Prevalence information 
was obtained from published literature. Pharmaceutical expenses of oral anti-
diabetic agents were analyzed excluding other medical costs. The cost of oral 
anti-diabetic agents was based upon list prices adjusted to co-payments, 
expressed in Chilean pesos 2012 (exchange rate 1US$ = 487.8 CH$). The market 
share of the different drugs was based upon QUALIDIAB Database, market 
studies and data provided by Bristol Myers Squibb. The budget impact is reported 
in terms of annual budget impact, per-member per-month (PMPM) and per-
patient per-month (PPPM). A Monte Carlo simulation (10,000 iterations) was done 
as part of the sensitivity analysis. RESULTS: The net budget impact estimated for 
the introduction of saxagliptin/metformin XR combined was $2,772,663 for the 
first year, $25,680,312 for the second year and $81,609,192 for the third year; the 
cumulative net budget impact was $110,062,166. PMPM was $0.23, $2.14 and $6.8 
for the first, second and third year respectively. PPPM was $9.2, $85.0 and $270.3 
each year, respectively. The cumulative impact in the total annual budget for 
oral anti-diabetic agents represented an increase of 1.6%. Monte Carlo simulation 
showed that cumulative budget impact varied from 1.1 to 1.8%. CONCLUSIONS: 
This study showed that the introduction of saxagliptin/metformin XR combined, 
as a treatment option for patients with T2DM, into the national health insurance 
system of Chile (FONASA) would have a minimal budgetary impact.  
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OBJECTIVES: The US burden of type-2 diabetes mellitus (T2DM) remains high 
and available treatment options leave patients with the need for innovative and 
safe treatments. This study assessed the financial consequences of adding 
alogliptin, a novel DPP4i, plus pioglitazone fixed dose combination (FDC) therapy 
to a US managed care health plan formulary. METHODS: An Excel-based model 
was developed to evaluate the therapy costs for patients uncontrolled on any 
pioglitazone- or DPP4i-containing regimen. Baseline costs were estimated for 
branded DPP4i, GLP1s, and FDCs using national market share and average daily 
consumption data from IMS National Prescription Audit (2012); wholesale 
acquisition costs were obtained from Medispan PriceRX (November 2012). 
Alogliptin/pioglitazone FDC adoption was estimated based on one-year expected 
uptake and was priced at parity with the leading DPP4i. Budget impact (BI) was 
calculated as total annual costs and costs per member per month (PMPM). 
Univariate sensitivity analyses were performed. T2DM prevalence and treatment 
data were obtained from published sources. The percentage of T2DM patients 
uncontrolled on pioglitazone and/or DPP4i was estimated from health plan 
claims analysis from January 2011 to September 2011. RESULTS: In a 
hypothetical health plan of 1,000,000 members, the estimated number of adult 
T2DM patients not on insulin and uncontrolled on any pioglitazone or DPP4i-
containing regimen was 13,779. Assuming proportional adoption of 
alogliptin/pioglitazone from all branded DPP4i agents, GLP-1, and FDCs, total 
annual pharmacy costs was $28,015,900 without alogliptin/pioglitazone and 
$28,024,195 with the new FDC, resulting in a BI of $8,295 ($0.00 PMPM, relative BI 
0.03%). In sensitivity analysis, it was assumed that the new FDC pulls share from 
DPP4i and GLP-1s only, resulting in BI of $12,838 ($0.00 PMPM, relative BI 0.04%). 
CONCLUSIONS: Inclusion of alogliptin/pioglitazone FDC on a formulary provides 
an additional effective treatment option and is budget neutral, having a 
negligible impact on the annual pharmacy budget.  
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OBJECTIVES: To estimate annual savings in Mexican public health care system 
by the usage of lixisenatide for the treatment of uncontrolled type-2 diabetes 
mellitus patients on basal insulin. METHODS: Two different GLP-1 analogues 
(lixisenatide vs exenatide <on National Formulary>) were evaluated from the 
perspective of public institution. A cost-minimization and budget impact 
analysis were conducted. Clinical efficacy was proved to be similar according to 
reported outcomes on a head-to-head clinical trial which included Mexican 
patients comparing the once-a-day administration of lixisenatide 20μg vs 
exenatide 10μg bid. Clinical response on 364 patients was evaluated; no 
statistical significance difference on reduction for fasting and postprandial 
glucose levels, as well as corporal weight loss, was reported; adverse events 
appeared to be less frequent on lixisenatide group than in exenatide group. 
Direct costs were considered on a decision tree with a temporary horizon of one 
year. No discount rate was included. Sensitivity analysis results on variables 
with highest degree of uncertainty were developed. Budget impact analysis was 
applied to different scenarios varying the estimated number of candidate 
patients to GLP-1 analogue treatment based on recent results reported on 
National Survey of Health and Nutrition 2012 (ENSANUT 2012). RESULTS: 
Estimated annual savings account for 279,000 USD. Budget impact reduction was 
established in 0.0008% for national public expenses in health and 0.0099% for 
therapeutic goods expenses in main public health institution in Mexico. 
Sensitivity analysis, showed robustness with base case. Market share scenarios, 
showed that increasing percentage of penetration (PP) of lixisenatide usage may 
result in lower impact to institutional budget (5.5 million USD for 0% PP to 5.2 
million USD for 100% PP) CONCLUSIONS: Glycemic goal level in type-2 diabetes 
patients can be achieved with the synergy of insulin and lixisenatide with a 
corporal weight reduction and cost savings compared to exenatide usage.  
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OBJECTIVES: To quantify the impact on medical costs of having an integrated 
medical and pharmacy benefit in the Diabetes Mellitus (DM) population. 
METHODS: Patients who had at least two diabetes ICD-9 codes or two diabetes 
medications refills between January 1, 2006 and December 31, 2006 were 
included. Patients with a diabetes diagnosis or diabetes medications within one 
year before the index date were excluded to ensure a treatment-naïve DM 
population. Only patients continuously enrolled from January 1, 2006 to 
December 31, 2011 were included in this retrospective cohort study. The Gemod 
model with Gamma distribution was utilized to adjust for the baseline disease 
comorbidity, age, gender, and account type differences. A total of 2090 patients 
met the eligibility criteria: 1087 in the integrated group (Members using an 
integrated medical and pharmacy benefit) and 1003 in the non-integrated group 
(Members using medical and pharmacy benefits from separate providers). 
RESULTS: The average unadjusted annual mean medical costs were $7,299 in the 
non-integrated group versus $5,561 in the integrated group (p<0.01). From year 1 
to year 5, the growth of adjusted mean medical costs was 53% in the non-
integrated group compared to 47% in the integrated group. The adjusted mean 
medical costs were higher in the non-integrated group (N=1003) than in the 
integrated group (N=1087) in each of the five years (p<0.01). While treatment 
naïve DM patients tended to have relatively low inpatient and emergency room 
costs, in each year, the integrated groups’ mean inpatient and emergency room 
costs were on average $568 lower when compared to the non-integrated group. 
This observed difference was not statistically significant. CONCLUSIONS: The 
DM patients in the integrated group had lower medical costs and lower inpatient 
and emergency room costs than their non-integrated counterparts. These results 
suggest a value to integrated health benefits; further research is required to 
elucidate the drivers of these observed savings.  
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OBJECTIVES: The prevalence of diabetes in the US and its economic burden 
continue to increase. Improving A1c levels is associated with patient-level cost 
savings. We combined a claims analysis with estimated cost data from published 
literature to predict cost savings at a health plan level when patients achieve 
specific A1c reductions. METHODS: Adult patients with diabetes and continuous 
health plan enrollment in 2011 were selected from the HealthCore Integrated 
Research DatabaseSM, representing a large national health insurer. The 
distribution of A1c levels in this sample was extrapolated to the health plan 
level. Estimated 1-year all-cause patient-level cost savings (medical plus 
pharmacy) associated with reducing A1c from ≥7% to <7% (ADA-recommended), 
as well as from a mean A1c reduction of ≥1%, were taken from published 
literature. Costs were adjusted to 2011 levels. RESULTS: Among all identified 
patients mean age was 60.1 years, 47.5% were female, 96.9% had type 2 diabetes, 
58.6% had ≥1 OAD fill and 22.9% had ≥1 insulin fill. A1c results were available for 
17.0% of patients. Extrapolating the A1c distribution to the health plan level 
(with 700,000 qualifying patients), 323,895 patients (46.3%) had an A1c ≥7% and 
96,556 (13.8%) had an A1c>9%. Mean cost reductions were estimated to be $536 
(≥7% to <7%) and $1,169 (1% A1c reduction) per patient. If 25% of patients 
currently at A1c ≥7% would achieve <7%, the estimated cost savings at the health 
plan level are $43.4m (±10%: $39.1m to $47.8m). Alternatively, evaluating patients 
with poor diabetes control (A1c>9%) only, assuming that 50% of these patients 
experience a mean A1c reduction of ≥1%, the estimated cost savings are $56.4m 
(±10%: $50.8m to $62.1m). CONCLUSIONS: Modest improvements in A1c levels, 
whether evaluated across the population or only in patients with poor control, 
would be associated with substantial cost savings at the health plan level.  
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OBJECTIVES: To investigate the cost of treatment success (cost of control) in 
patients with type-2 diabetes (T2DM) achieving a composite endpoint of blood 
glucose, weight and hypoglycaemia with liraglutide 1.2mg once-daily as 
compared to other relevant antidiabetic therapies in China. METHODS: To 
measure the ability to obtain control of diabetes, a single composite endpoint 
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A161 
 
 
was defined as achieving HbA1c below 7% without weight gain and with no 
hypoglycaemic events in 26 weeks. With the assumption that a payer would be 
interested in paying only for successfully treated patients, cost of control was 
subsequently defined as the price per patient achieving the composite endpoint. 
The relevant comparator drugs, glimepiride, rosiglitazone and insulin glargine, 
were defined as those found both in the ‘Liraglutide Effect and Action in 
Diabetes’ clinical trial programme and on the China national drug 
reimbursement list. The number needed to treat (NNT) for patients achieving the 
composite endpoint at week 26 was also investigated. Costs of drug, needle and 
self-monitoring blood glucose were accounted based on the marketed retail price 
published by National Development and Reform Commission in 2012 Chinese 
value. RESULTS: The NNT for patients on liraglutide 1.2mg was 3.1 for achieving 
the composite endpoint, compared to between 6.7 and 16.7 for the three 
comparator drugs. This lead to the cost per successfully treated patient to be 
between 17% and 68% higher with glimepiride, insulin glargine and rosiglitazone 
compared to liraglutide 1.2mg in China. CONCLUSIONS: By assessing the NNT to 
achieve HbA1c below 7% with no weight gain and no hypoglycaemic events and 
the cost per patient achieving this composite endpoint, liraglutide 1.2mg was a 
cost-saving approach for T2DM patients in comparison with glimepiride, insulin 
glargine and rosiglitazone in a Chinese setting.  
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OBJECTIVES: Compare health care resource use and costs in patients with type 2 
diabetes mellitus (T2DM) treated with saxagliptin or sitagliptin in the 6 months 
following treatment initiation. METHODS: Patients with T2DM treated with 
saxagliptin (N=13,929) or sitagliptin (N=36,813) in 2010 or later were identified in 
the Truven MarketScan database of commercially insured beneficiaries. Patients 
were required to have no claims of saxagliptin or sitagliptin in the 6 months 
prior to treatment initiation, ≥6 months of continuous eligibility before and after 
initiation (baseline and study period, respectively), and be 18 or older. 
Demographic characteristics and comorbidities were evaluated in the baseline 
period. All-cause and diabetes-related resource use and costs were evaluated 
during the study period. Chi-squared and Wilcoxon rank sum tests assessed 
differences in resources use rates and costs. GLM regression with a log link and 
gamma distribution estimated the treatment effect on study period costs, 
adjusting for baseline characteristics and costs. RESULTS: During the study 
period, compared with sitagliptin patients, saxagliptin patients experienced 
lower rates of all-cause hospitalization, emergency department visits, and other 
medical visits (7.2% vs. 10.6%, 14.1% vs. 17.5%, and 67.0% vs. 70.4%, respectively; 
p<0.001). All-cause medical and total costs were lower for saxagliptin patients 
than sitagliptin patients ($4,555 vs. 5,921; $7,346 vs. $8,797; all p<0.001). 
Substantial costs were attributable to hospitalizations, which were less costly for 
saxagliptin patients ($1,477 vs. $1,992; p<0.001). Diabetes-related medical and 
total costs were also significantly lower for saxagliptin patients ($1,084 vs. $1,454; 
$2,445 vs. $2,828; all p<0.001). After adjusting for baseline characteristics, 
significant differences in medical and total costs persisted (all-cause: $5,073 vs. 
$5,535; $7,802 vs. $8,302; diabetes related: $1,149 vs. $1,387; $2,510 vs. $2,772; all 
p<0.001). CONCLUSIONS: Patients initiating treatment with saxagliptin had 
lower resource use and costs in a 6-month follow-up period than patients 
initiating with sitagliptin.  
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OBJECTIVES: To compare annual costs between diabetic macular edema (DME), 
diabetic retinopathy (DR), and diabetes on the direct and indirect costs of US 
employees versus controls without diabetes. METHODS: Analysis of 2001-2012 
administrative claims from the HCMS Reference Database which contains 
anonymous data from >20 geographically-dispersed US employers (1.7 million+ 
employees) including manufacturing, insurance, retail, transportation, 
telecommunications. Employees with DME, DR and Diabetes were identified by 
ICD-9 codes. For DME/DR subjects, the index date was the date of the initial 
claim, and for the other cohorts, the average of DME/DR index dates. All subjects 
were required to have ≥12 months follow-up post index date. Cohorts were 
compared using two-part regression (logistic then generalized linear) models 
controlling for demographics and job-related information. Only subjects eligible 
for a benefit were included in the models for that benefit. All annual direct and 
indirect cost outcomes were inflation-adjusted to 2012 by the appropriate CPI 
index. RESULTS: The analysis identified 426,549 employees (DME=528; DR=1441; 
Diabetes=18,639; Controls=405,931). Medical costs for the cohorts were: 
DME=$12,125; DR=$13,547; Diabetes=$6,815; Controls=$3,326; Rx costs were: 
DME=$3,338; DR=$3,733; Diabetes=$2,502; Controls=$849. Medical and Rx costs 
were significantly different between all cohorts (P<0.0001) except DME-vs-DR. 
Indirect components: Sick Leave: DME=$1009; DR=$924; Diabetes=$830; 
Controls=$606; Short-term Disability: DME=$705; DR=$760; Diabetes=$483; 
Controls=$259; Long-term Disability: DME=$136; DR=$240; Diabetes=$66; 
Controls=$29; Workers’ Compensation: DME=$119; DR=$75; Diabetes=$229; 
Controls=$189. All DR-vs-Controls and Diabetes-vs-Controls comparisons were 
significant (P<0.03). Sick Leave and Short-term Disability for the other cohort 
pairs were also significant (P<0.05), except DME-vs-DR. Workers’ Compensation 
was significantly lower for DME-vs-Diabetes and DR-vs-Diabetes. CONCLUSIONS: 
This analysis shows the significant impact of DME and DR on employee direct 
and indirect costs across a variety of benefits. Overall employees with Diabetes 
were $5667 more expensive than Controls, and DME and DR resulted in 
incremental costs of $6507 and $8354 more than those with Diabetes, 
respectively.  
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OBJECTIVES: Strict control of glycemia in diabetic patients is impeded by the risk 
of hypoglycemia, especially when insulin is used. However, not all insulins have 
the same risk of hypoglycemia. The aim of this study was to study the cost of 
insulin related hypoglycemia requiring hospitalization (at least one overnight 
stay) in type-1 and 2 diabetes in Belgium. METHODS: A retrospective database 
study was conducted using the longitudinal IMS Hospital Disease Database (HDD 
2009), covering 34.3% of Belgian hospital beds. In this database hypoglycemic 
events can be identified based on ICD-9 codes (Diabetes hypoglycemic 
coma/insulin coma: 250.3; Diabetic hypoglycemia/hypoglycemic shock: 250.8; 
Anti-diabetic agent poisoning and adverse events: E932.3, 962.3). Number of stays 
for hypoglycemia, average length of stay (LOS) and on intensive care (ICU), in 
hospital mortality, re-hospitalizations for hypoglycemia and costs were 
estimated using SAS software. RESULTS: In the HDD 2291 patients were 
hospitalized for hypoglycemia due to insulin. In 2009, each patient had on 
average 1.12 hospitalizations. Eighty-five percent of those stays were in patients 
older than 55. The average LOS was 20.69 days (with 0.31 days on ICU) strongly 
driven by stays in the population >55 years (13 vs. 22 days; p<0.0001). Mortality 
during hospitalization was 6.78% driven by the age group older than 65 (3.49% vs. 
8.20%; p<0.0001). The average cost of a hospitalization was €11,066 [€10,077-
€11,359]. CONCLUSIONS: Hospitalizations for hypoglycemia due to insulin are 
expensive and result in an important in hospital mortality. Especially in the 
older age (>55), the costs for the health care payer are high due to extensive LOS. 
Interventions that can help reduce the risk of hypoglycemia, and as a 
consequence the burden on hospitals and society, without compromising 
glycemic control will help further improve diabetes management.  
 
PDB34  
TREND IN ECONOMIC BURDEN OF DIABETES IN URBAN CHINA FROM 2009 TO 
2011  
Wu EQ1, Xie J2, Du EX1, Liu M3, Liu G3 
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Peking 
University, Beijing, China  
OBJECTIVES: To estimate the trend in direct and indirect costs among patients 
with diabetes in urban China from 2009 to 2011. METHODS: Data were obtained 
from the 2009-2011 Urban Resident Basic Medical Insurance (URBMI) household 
survey in 9 cities. Households were sampled to be representative of all 
households in these cities. Patients who self-reported to have a diabetes 
diagnosis were included. Annual costs per patient were estimated from the 
societal perspective, which included direct medical, direct non-medical and 
indirect costs. Direct medical costs included outpatient service, outpatient drug 
and inpatient costs. Outpatient service and drug costs were reported for the past 
2 weeks and extrapolated to 1 year. Inpatient costs were estimated based on the 
number of hospitalizations during the past year and costs for the most recent 
hospitalization. Direct non-medical costs included transportation, 
accommodation costs, etc. Indirect costs due to absenteeism were estimated for 
employed patients based on mean annual national wage of urban employees in 
China. All costs were inflated and converted to 2011 USD. RESULTS: A total of 
3,253 patients with self-reported diabetes diagnosis (N=1,078 in 2009, 1,114 in 
2010 and 1,061 in 2011) were included, with 49.1% female and a mean age of 64.0 
years. Mean annual direct medical costs were $1,303.2, $1,460.1 and $2,072.0 in 
2009, 2010 and 2011, respectively. Mean outpatient drug costs were $565.8, $683.7 
and $1034.5 in the three years, respectively, accounting for 43.4% to 49.9% of the 
direct medical costs. Insurance covered 42.8% to 45.5% of the direct medical 
costs. Mean annual direct non-medical costs were $111.9, $204.3 and $619.6 in 
2009, 2010 and 2011, respectively (P=0.224). The corresponding indirect costs 
were $135.0 (N=199), $201.3 (N=172) and $180.3 (N=167). CONCLUSIONS: Direct 
medical costs, outpatient drug costs and direct non-medical costs of diabetes 
increased numerically from 2009-2011 in urban China .  
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OBJECTIVES: To estimate medical expenditure for people with diabetes in Urban 
Employee Basic Medical Insurance (UEBMI) program in 2011 in Beijing, China. 
METHODS: Claims data from Beijing UEBMI database during 2010.10.01 to 
2011.09.30 was extracted with the criterion of people diagnosed with “diabetes 
mellitus” during this period. The Sum_All Medical method was used for 
